Dr. Kenneth Aldape from the U.S. National Cancer Institute Joins Pangea Biomed’s Scientific Advisory Board
Dr. Aldape will work together with the biotech business to assist the development of their cancer action predictor platform
Tel Aviv, Israel-- WEBWIRE-- Wednesday, October 2, 2024
Pangea Biomed, the start-up behind the worlds most sophisticated cancer reaction predictor, ENLIGHT, revealed that Dr. Kenneth D. Aldape, M.D., has actually signed up with the business clinical board of advisers.
Dr. Aldape, an internationally acknowledged molecular neuropathologist, is Chief of the National Cancer Institute (NCI) Lab of Pathology. He is a leading figure in his field, respected for his prominent work utilizing methylation patterns (chemical adjustments) for the sub-classification of brain growths, which is thought about the most precise tool for brain growth medical diagnosis.
...